New Delhi: Breast cancer is the top cancer victimising women in the developed as well as in the developing world.
Unfortunately, low and middle-income countries are at a higher risk of breast cancer due to lack of timely diagnosis.
Breast cancer treatment depends on the stage of cancer. Traditional therapies normally consist of chemotherapy, radiation, hormone therapy and surgery.
However, there are many breast cancer patients who don’t respond to the traditional methods and become resistant.
So, in what could be well on its way to become a breakthrough, scientists – including an Indian-American researcher – have identified a molecule that can help treat breast cancer giving hope to patients who have become resistant to traditional therapies.
The first-in-class molecule shuts down oestrogen-sensitive breast cancer in a new way, researchers said. First-in-class drugs are those that work by a unique mechanism – in this case a molecule that targets a protein on the oestrogen receptor of tumour cells.
The potential drug offers hope for patients whose breast cancer has become resistant to traditional therapies. “This is a fundamentally different, new class of agents for oestrogen-receptor-positive breast cancer,” said Ganesh Raj, professor at the University of Texas Southwestern (UT Southwestern) Simmons Cancer Center. “Its unique mechanism of action overcomes the limitations of current therapies,” Raj said.
All breast cancers are tested to determine if they require oestrogen to grow and about 80% are found to be oestrogen-sensitive, researchers said. These cancers can often be effectively treated with hormone therapy, such as tamoxifen, but as many as a third of these cancers eventually become resistant, they said.
The new compound is a potential highly effective, next- line treatment for these patients, said Raj. Traditional hormonal drugs, such as tamoxifen, work by attaching to a molecule called the oestrogen receptor in cancer cells, preventing oestrogen from binding to the receptor, a necessary step for cancer cells to multiply.
However, the oestrogen receptor can mutate and change its shape over time so that the treatment drug no longer fits neatly with the receptor. When this happens, the cancer cells start multiplying again. “There has been intense interest in developing drugs that block the ability of the oestrogen receptor – the prime target in most breast cancers – from interacting with the co-regulator proteins that cause a tumour’s growth,” said David Mangelsdorf, professor at UT Southwestern.
Blocking such “protein-protein interactions” has been a dream of cancer researchers for decades. The drug works by blocking other molecules – proteins called co-factors – that also must attach to the oestrogen receptor for cancer cells to multiply.
The new molecule, dubbed ERX-11, mimics a peptide, or protein building block. So far, it has been tested in mice and in cancer cells removed from patients and works well in both models, and there have been no signs of toxicity in the tests.
If successfully translated to a human therapy, another advantage of ERX-11 is that it could be taken orally by patients, rather than as an infusion. The researchers are hoping to get a clinical trial under way in about a year. The notion of blocking protein co-factors has implications for treatment of other cancers as well.
(With PTI inputs)